Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077833 | 0.83 | FDPS (0.45) | FDPSFPR2KDM4ETBXAS1 | |
| SCHEMBL3794186 | 0.83 | L3MBTL1 (0.48) | FDPSL3MBTL1BCHESTK17BSTK17A | |
| SCHEMBL4713820 | 0.81 | NPSR1 (0.47) | L3MBTL1BCHESTK17BSTK17ATBXAS1 | |
| SCHEMBL4734573 | 0.78 | STK17B (0.47) | L3MBTL1STK17BSTK17ATBXAS1NPSR1 | |
| SCHEMBL12647368 | 0.77 | TBXAS1 (0.49) | L3MBTL1STK17BSTK17ALMNATBXAS1 | |
| SCHEMBL6585454 | 0.76 | TDP1 (0.51) | L3MBTL1STK17BSTK17ALMNATBXAS1 | |
| SCHEMBL27611392 | 0.74 | L3MBTL1 (0.55) | L3MBTL1KDM4ENPSR1TDP1 | |
| SCHEMBL3845409 | 0.73 | MEN1 (0.42) | BCHESTK17BSTK17ANPSR1ATM | |
| SCHEMBL23367084 | 0.72 | L3MBTL1 (0.41) | L3MBTL1BCHESTK17BSTK17AKDM4E | |
| SCHEMBL4151559 | 0.72 | FDPS (0.45) | FDPSL3MBTL1KDM4ETBXAS1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7173053-B2 | N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-1339400-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | VERNALIS OXFORD LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1339400-A1 | HYDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002041886-A1 | YDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BAKTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | FPR1, FPR3, FPR2 | FDPS 1043/4885L3MBTL1 167/4885JAK1 3194/4885 |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | HNMT, ALKBH1, BAK1 | FDPS 739/4885L3MBTL1 67/4885JAK1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.